poisar

Stocks · News reference

Imunon Announces Exchange Of $1.2M Debt For Non-Convertible Series B Preferred Stock

BenzingaBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — Imunon, Inc. (IMNN)

    Filed: 2026-11-12 AccNo: 0001493152-26-051202 Size: 366 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

  2. Globenewswire IncNa

    IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer

    IMUNON announced new translational data from its Phase 2 OVATION 2 study showing that IMNN-001, when combined with standard chemotherapy, increased anti-tumor T-cell activity and improved median overall survival by 14.7 months in advanced ovarian cancer patients. The data demonstrates the drug's mechanism of converting the tumor microenvironment from immunologically 'cold' to 'hot,' supporting the ongoing Phase 3 OVATION 3 trial.